Numbers

Codex View

Why The Stock Trades Here

Unihealth is trading as a high-growth small-cap hospital platform where the market is rewarding accelerating H1 FY2026 profitability and expansion optionality, but still pricing below large listed hospital peers on P/E. The single rerating/derating metric is now cash conversion: if operating cash flow normalizes versus reported earnings, the multiple can expand; if debtor days stay elevated and free cash flow remains negative, multiple risk rises.

Price And Valuation Snapshot

Despite a sharp run-up, UNIHEALTH still screens at a P/E discount to both sector reference and major listed hospital peers, implying the market is not yet capitalizing it as a fully de-risked compounder.

Revenue And Earnings Power

The core earnings trend is clear: FY2020–FY2025 sales CAGR is about 20.6%, while recent half-year numbers show a step-up in profitability (Q2 FY2026 net profit at ₹29 Cr vs ₹9 Cr in Q2 FY2025). The valuation debate is less about growth visibility and more about cash realization quality.

Critical Chart: Reported Profit Vs Usable Cash

The cash-flow miss is explained by working-capital intensity: debtor days moved from 180 (FY2022) to 328 (FY2025), with cash-conversion-cycle days reaching 306.

Balance Sheet And Per-Share Economics

Deleveraging is real and meaningful, but it came with a major equity-base reset from FY2024 onward. Per-share compounding now depends on translating higher reported profit into repeatable free cash flow.

Industry-Specific Operating Mix

Revenue remains highly concentrated in the core hospitals/medical-centres engine, and geography concentration remains high with Uganda at 90.93% of H1 FY2026 revenue mix (from management presentation), which supports focus but leaves valuation sensitive to local execution and receivables discipline.

Peer Positioning

UNIHEALTH combines stronger operating margin than some larger peers with materially smaller scale and a sharper working-capital drag. That combination explains why it can look statistically cheap on P/E but still face quality discounting.

What The Numbers Say Next

The numbers confirm strong top-line growth, margin expansion, and balance-sheet repair. They contradict a clean “high-profit = high-cash” story, with FY2025 showing negative CFO/FCF despite higher profits. Next quarter, watch debtor days and CFO recovery first, then assess whether valuation discount to larger hospital peers should close.

Claude View

Unihealth trades at 29x trailing earnings – a steep discount to Indian hospital peers at 50-90x – because the market correctly prices in single-hospital concentration risk, sovereign payer dependency, and negative free cash flow. The single metric most likely to rerate this stock is consolidated debtor days: if the India expansion brings cash-paying patients and pulls debtor days from 328 toward 180, the market will close the valuation gap. If receivables keep expanding, the reported profits remain paper-only.

Valuation Snapshot

The stock has risen 3.4x from its IPO price of ₹132 (Sep 2023) and 4.1x from its all-time low of ₹109 (Aug 2024). The 52-week range of ₹134-479 reflects a market that went from ignoring a micro-cap SME listing to aggressively pricing in H1 FY26 margin expansion and India expansion plans.

Revenue and Earnings Power

Revenue has compounded at ~21% annually from ₹22 Cr (FY20) to ₹56 Cr (FY25). Net profit inflected from a ₹1 Cr loss in FY20 to ₹15 Cr in FY25, boosted by a Uganda tax holiday that cut the effective tax rate from 24% to 12%. Without the tax holiday, FY25 net profit would have been closer to ₹13 Cr and the trailing PE closer to 34x.

Quarterly Trajectory – The Inflection

H1 FY26 is the inflection point: revenue surged 56% YoY to ₹67 Cr with operating margins expanding to 48% as the Uganda hospital's ARPOB jumped from ~₹24K to ~₹40K/day through super-specialty additions. Net profit of ₹29 Cr in H1 FY26 already exceeds full-year FY25 profit of ₹15 Cr. The annualized H1 FY26 run-rate implies a forward PE of ~12x – if sustainable.

Margin and Tax Tailwinds

Two tailwinds flattered FY25-H1 FY26 profitability simultaneously: (1) operating leverage at the Uganda hospital as ARPOB nearly doubled, and (2) a 10-year Uganda income tax holiday from Jul 2024. The tax rate collapsed from 24% in FY24 to 4% in H1 FY26. Both effects are real but neither is replicable at the Indian facilities where tax rates will be normal and margins will start at 15-18%.

The Cash Conversion Problem

This is the most important chart for Unihealth. FY25 net profit hit a record ₹15 Cr while operating cash flow turned negative at -₹3 Cr and free cash flow plunged to -₹13 Cr. Cumulative net profit over FY20-FY25 was ₹41 Cr; cumulative operating cash flow was just ₹17 Cr. The ₹24 Cr gap sits in receivables – an involuntary, interest-free loan to the Ugandan military.

Cash conversion collapsed from 2.25x in FY22 to negative in FY25. Indian hospital peers typically convert 70-90% of reported profits to operating cash. Unihealth's 3-year average is 9%.

Debtor Days – The Receivables Problem

Debtor days surged from 180 in FY22 to 328 in FY25. The company is financing almost a full year of revenue on its balance sheet. The Uganda military (₹82 Cr of ₹112 Cr receivables) pays on 9-13 month cycles. Management promises that cash-and-insurance patients in India will bring consolidated debtor days below 180 – this is the single most important claim to verify.

Balance Sheet – Clean But Stretching

The Sep 2023 IPO transformed the balance sheet: equity jumped from ₹26 Cr to ₹70 Cr, borrowings fell from ₹39 Cr to ₹15 Cr. Debt-to-equity improved from 1.5x to 0.15x. However, H1 FY26 reveals rapid expansion: total assets nearly doubled to ₹221 Cr, fixed assets jumped from ₹40 Cr to ₹72 Cr, CWIP reached ₹10 Cr, and other liabilities surged from ₹15 Cr to ₹78 Cr – likely lease obligations from the India hospital build-out.

Return on Capital – Dipping Through Expansion

ROCE peaked at 22% in FY23 and has declined to 17% as the IPO-expanded equity base dilutes returns. This is the expected pattern during heavy investment. The question is whether ROCE can hold above 15% through the ramp-up period – still matching or exceeding most listed peers.

Shareholding Pattern

Promoter holding has edged up from 68.8% to 69.1% – a positive signal. FIIs exited post-IPO. DII interest is slowly emerging (0.75% in Sep 2025). The shareholder count of ~1,058 means this remains a thinly traded stock with significant liquidity risk.

Peer Valuation Comparison

Unihealth trades at roughly half the PE of Medanta (50.5x) despite similar ROCE (17.2% vs 19.7%). The discount reflects three structural realities: Unihealth is 40-150x smaller, operates primarily in Africa rather than India, and generates negative free cash flow versus peers' strong cash conversion. The market is right to discount these risks, but the magnitude creates optionality if India execution succeeds.

Revenue Scale in Context

Unihealth's 21% revenue CAGR is competitive with KIMS (22%) and Medanta (20%), but the base effect matters enormously: growing from ₹22 Cr to ₹56 Cr is operationally trivial compared to KIMS growing from ₹1,123 Cr to ₹3,035 Cr. The H1 FY26 YoY growth of 56% is driven by ARPOB jumps at a single hospital, not multi-facility scaling.

What the Numbers Confirm, Contradict, and Demand

The numbers confirm that Unihealth's Uganda hospital is a genuinely high-margin business with pricing power – the ARPOB jump and margin expansion in H1 FY26 are real and impressive for a 120-bed facility. The 29x PE discount to 50-90x peers creates meaningful upside if execution delivers.

The numbers contradict any narrative of operational maturity. Negative free cash flow, 328 debtor days, surging other liabilities, and zero dividend capacity indicate a company profitable on paper but cash-constrained in practice. The 33% operating margin flatters a business that cannot collect its revenue on time.

What must be watched next quarter: (1) consolidated debtor days – any decline proves the India cash-mix thesis; (2) Navi Mumbai occupancy ramp – below 40% in Q3 FY26 would signal competitive headwinds; (3) the ₹78 Cr other liabilities jump – whether these are lease obligations or something else needs clarification.